linjc16/ctgov huggingface dataset:
Applying Artificial Intelligence to Optimize Early-stage Hepatocellular Carcinoma Treatment Based on Multi-modal Image

Study Overview
=================
Brief Summary
-----------------
This study intends to establish two prognostic models based on contrast-enhanced ultrasound (CEUS) and dynamic enhanced magnetic resonance (DE-MRI) multimodal images: prognostic model of liver cancer patients after hepatectomy and prognostic model of liver cancer patients after radiofrequency ablation. Combined with artificial intelligence imaging omics, traditional imaging omics and clinical information, to predict and compare the prognosis of two different treatment methods for early liver cancer, so as to realize the individual selection of treatment methods for early liver cancer patients

Official Title
-----------------
Artificial Intelligence to Optimize Early-stage Hepatocellular CarcinomaTreatment Based on Multi-modal Image

Conditions
-----------------
Hepatocellular Carcinoma

Intervention / Treatment
-----------------
* Other: CEUS and CEMRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primary single hepatocellular carcinoma confirmed by histology or cytology, with a maximum diameter ≤5.0 cm; Good liver function, Child-Pugh grade A; No serious dysfunction of heart, lung, kidney and other important organs ④ Liver resection or radiofrequency ablation was performed in our hospital, and the study protocol and follow-up procedure were followed. Exclusion Criteria: Patients who cannot perform DCE-MRI examination due to metal implants in the body ② Patients who had received other treatment before DCE-MRI or CEUS; Invisible lesions, diffuse lesions or poor DCE-MRI/CEUS image quality under CEUS; ④ Drug abuse, clinical or psychological or social factors that make informed consent or study implementation affected.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| SR<br> | Other: CEUS and CEMRI<br>* contrast-enhanced ultrasound and contrast-enhanced MRI examination<br>|
| RFA<br> | Other: CEUS and CEMRI<br>* contrast-enhanced ultrasound and contrast-enhanced MRI examination<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Good/Poor overall survival |  | 2022/12/01-2025/12/01 |
Bioequivalency Study of 450 mg Lithium Carbonate Under Fed Conditions

Study Overview
=================
Brief Summary
-----------------
The objective of this study was to assess the bioequivalence of two Roxane lithium carbonate 450 mg extended release tablet formulations compared to GlaxoSmithKline's Eskalith CR 450 mg extended release tablet under fed conditions using a single-dose, randomized, three-treatment, three-period, six-sequence crossover design.

Official Title
-----------------
A Single Dose, Three-Treatment, Three-Period, Six-Sequence Crossover Bioequivalency Study of 450 mg Lithium Carbonate Extended Release Tablets Under Fed Conditions

Conditions
-----------------
Bipolar Disorder

Intervention / Treatment
-----------------
* Drug: Lithium


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening. Exclusion Criteria: Participation in a clinicl trial within 30 days prior to study initiation. Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs.

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Lithium|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bioequivalence |  | Baseline, Three period, Fourteen day washout |
Study of Dietary N-3 Fatty Acids in Patients With Retinitis Pigmentosa and Usher Syndrome

Study Overview
=================
Brief Summary
-----------------
OBJECTIVES: I. Examine the concentration of docosahexanoic acid (DHA) and other n-3 fatty acids in plasma, erythrocyte, and adipose tissue in patients with various forms of retinitis pigmentosa and Usher syndrome. II. Determine the synthesis and catabolism of DHA from linolenic acid in these patients. III. Determine the synthesis, absorption, and catabolism of DHA under different dietary conditions in these patients.

Detailed Description
-----------------
PROTOCOL OUTLINE: Patients may participate in one or more of the arms of this study. Arm I (adipose tissue study): Adipose tissue is collected from the buttocks of patients with Usher II retinitis pigmentosa (RP), patients with non-Usher RP, and control subjects. Dietary histories are obtained from all patients and subjects. Arm II (isotope study): Patients meeting the same criteria as in arm I receive oral D5-labeled linolenic acid and oral D4-labeled linolenic acid that is dissolved in oil and incorporated into foods. Subjects must avoid eating fish and shellfish during the 35 days of the isotope study. Blood samples are collected at 0, 8, 24, and 48 hours, daily on days 3-7, and then on days 10, 18, and 35. Arm III (flaxseed oil feeding): Patients with all types of RP and control subjects receive flaxseed oil, a form of linolenic acid, for 12 weeks. Subjects may also receive high oleic safflower oil or olive oil as a control fat for 12 weeks. Subjects complete a diet history at the end of each fatty acid supplementation period. All subjects must follow a diet free of seafood and fish oil supplements.

Conditions
-----------------
Usher Syndrome, Retinitis Pigmentosa

Participation Criteria
=================
Eligibility Criteria
-----------------
PROTOCOL ENTRY CRITERIA: Retinitis pigmentosa, including: Usher syndrome (types I and II) Simplex The following inheritance patterns eligible: X-linked recessive; Autosomal dominant; Autosomal recessive

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Usher syndrome, ophthalmologic disorders, rare disease, retinitis pigmentosa
A Prospective Study Evaluating the Performance of Nanotite Osseotite Implants When Placed by Graduate Student Programs

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the contributions of the Nanotite implant design when used by graduate students in their first year of placing implants.

Detailed Description
-----------------
This multicenter, prospective, randomized-controlled study will compare the performance of the Nanotite vs. the standard Ossotite implants when placed by graduate students with little or no prior experience. Enrolled patients will have the study site(s) randomized to either a Nanotite (test) or an Osseotite (control) implant. The manner of treatment observed at the participating center will be followed for this study. Study Hypothesis: The performance of the Nanotite implant in this study will be no different than or superior to that of the Osseotite implant placed during the early period of graduate student training.

Official Title
-----------------
A Prospective Randomized-controlled Evaluation of Nanotite and Osseotite Surfaced Implant Performance in Graduate Student Programs

Conditions
-----------------
Tooth Disease, Partial Edentulism

Intervention / Treatment
-----------------
* Device: Nanotite dental implant
* Device: Osseotite dental implant


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients of either sex and of any race, 18 years of age or older patients for whom a decision has already been made to use dental implants for treating edentulism in the mandible or maxilla Exclusion Criteria: patients who are known to be pregnant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: implant types were randomized- 2 different surface treatments
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Nanotite implant<br>Nanotite dental implant | Device: Nanotite dental implant<br>* Nanotite root form titanium dental implant<br>* Other names: Nanotite endosseous dental implant;|
| Active Comparator: Osseotite implant<br>Osseotite dental implant | Device: Osseotite dental implant<br>* Osseotite Root form titanium dental implant<br>* Other names: Osseotite endosseous dental implant;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Integration Success of the Implant |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dental implants, Nanotite implant, Osseotite implants, multicenter, randomized, clinical study, partial edentulism, prosthesis
Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 Diabetes

Study Overview
=================
Brief Summary
-----------------
This trial is conducted in Europe. The aim of this trial investigate the the long-term safety of biphasic insulin aspart 30 in subjects with type 2 diabetes.

Official Title
-----------------
A Multi-National, Multi-Centre, Open-Labelled Extension Study Assessing the Long-Term Safety of Biphasic Insulin Aspart 30 in NovoMix®30 FlexPen™ in Type 2 Diabetic Patients Previously Treated in BIAsp-1236

Conditions
-----------------
Diabetes, Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Drug: biphasic insulin aspart


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed informed consent obtained before any trial-related activities Completed the trial BIAsp-1236 Exclusion Criteria: Planned changes in use of any prescription medication that may interfere with glucose regulation Known or suspected allergy to trial products or related products Women who are having the intention of becoming pregnant, or are judged not to be using adequate contraceptive measures Any other significant condition or concomitant disease or any condition that would interfere with participation as judged by the Investigator

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: BIAsp<br> | Drug: biphasic insulin aspart<br>* Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily before breakfast and evening meal<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Hypoglycaemic episodes |  |  | 
| Occurrence of adverse events |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HbA1c (glycosylated haemoglobin) |  |  | 
| Prandial increment in blood glucose |  |  | 
| 7-point blood glucose profile |  |  |
A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to permit access to SU011248 for treatment use by patients with GIST given the following conditions: a) patients undergo screening, but are not eligible for participation in ongoing clinical studies such as A6181004; AND b) patients have GIST which standard treatments have not been able to control with acceptable toxicity AND c) patients have the potential to derive clinical benefit from treatment with SU011248.

Detailed Description
-----------------
Given that an Expanded Access study does not meet the definition of a controlled clinical investigation, and as such, is not considered an applicable drug clinical trial per NIH, Basic Results for such studies are not required to be reported. Protocol A6181036 has been identified as an Expanded Access trial, and has been registered to ClinicalTrials.gov, however Basic Results will not be posted.

Official Title
-----------------
A Treatment Protocol For Patients With Gastrointestinal Stromal Tumor Who Are Ineligible For Participation In Other SU011248 Protocols And Are Refractory To Or Intolerant Of Imatinib Mesylate

Conditions
-----------------
Gastrointestinal Neoplasm

Intervention / Treatment
-----------------
* Drug: Sutent


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically proven Gastrointestinal Stomal Tumor (GIST) that is not amenable to standard therapy Undergone screening and found to be ineligible for participation in ongoing SU011248 clinical studies Patient judged to have potential to derive clinical benefit from SU011248 treatment by the treating physician Failed prior treatment with imatinib mesylate, defined as either progression of disease or significant toxicity during treatment with imatinib mesylate that precluded further treatment Male or Female, 18 years or older Resolution of all acute toxicities of prior therapies Adequate organ function Exclusion Criteria: Symptomatic congestive heart failure, myocardial infarction, or coronary artery bypass graft in the last 6 months, or ongoing severe or unstable angina or any unstable arrhythmia requiring medication Symptomatic central nervous system metastases Serious acute or chronic illness Current treatment on another clinical trial Pregnant or breastfeeding.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Sutent|Sutent, 25, 37.5, or 50 mg daily|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Laryngomalacia No Longer An Ambiguity

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to expose some of the factors that may be associated or predisposing to development of laryngomalacia.

Detailed Description
-----------------
Laryngomalacia is the most common congenital malformation of the larynx and it is a self-limited disorder. It is the most common cause of stridor in newborns and infants. It results from an abnormal prolapse of supraglottic structures during inspiration. Despite its widespread prevalence, the etiology of laryngomalacia is unclear. Most infants will squeaky but otherwise well. Although affected patients do not exhibit much in the way of other physical symptoms, the unusual voice is worrisome to their parents.

Official Title
-----------------
Laryngomalacia No Longer An Ambiguity

Conditions
-----------------
Laryngomalacia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Babies delivered with laryngomalacia with ≥ 37 weeks of gestation Delivered with birth weights ≥ 2.5 kg No history of natal or post-natal complications From the same community Exclusion Criteria: Pre-term babies History of natal or post-natal complications

Ages Eligible for Study
-----------------
Minimum Age: 14 Days
Maximum Age: 2 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control<br> | |
| Laryngomalacia Cases<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Laryngomalacia, Factors Associated or Predisposing
The Predictors and Patient Versus Parental Perceptions of Health-Related Quality of Life in Pediatric Chronic Pain

Study Overview
=================
Brief Summary
-----------------
This study is intended to provide additional insight into the factors affecting health-related quality of life with pediatric chronic pain as perceived by the patient versus his or her parents.In doing so, additional insight into the subjective interpretation the pediatric chronic pain experience will be gained. The four objectives of this study will be (a) to examine further the relationship between patient self-reported health-related quality of life and parent proxy-reported health-related quality; (b) to identify what biological, psychological, and/or social factors are the strongest predictors of a pediatric chronic pain patient's self-reported pain intensity and self-reported health-related quality of life, in a diverse cohort of patients referred to and subsequently treated by an anesthesiology-based yet interdisciplinary pediatric chronic pain medicine program; (c) to assess the effect of patient-specific, pain-focused biopsychosocial treatment regimen on pain intensity and health-related quality of life; and (d) to determine the effect of patient/parental satisfaction with on-going health care on their compliance with and uptake of the pain treatment regimen.

Official Title
-----------------
The Predictors and Patient Versus Parental Perceptions of Health-Related Quality of Life in Pediatric Chronic Pain

Conditions
-----------------
Pediatric Chronic Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: outpatients ranging between 8 years and 18 years of age directly referral from either their primary care physician or another specialist physician Exclusion Criteria: patients in whose biologic families English is not the primary, native language patients suffering from severe cognitive dysfunction (i.e., mental retardation) patients with a life-expectancy of less than three months at the time of initial clinical evaluation

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Heath-related quality of life | PedsQLTM 4.0 and 36-Item Short-Form Health Survey Version 2 (SF-36v2) | Baseline at time of initial outpatient clinic visit | 
| Pain intensity and functional disability | Pediatric Pain Questionnaire (PPQ) and Functional Disability Inventory (FDI) | Baseline at the time of initial outpatient clinic visit |
Dose Ranging Study With LT, Monotherapy, PPAR

Study Overview
=================
Brief Summary
-----------------
A Randomized, Double-Blind, Dose-Ranging, Dose Comparison-Controlled Trial to Determine the Safety and Efficacy of BMS-298585 in Subjects with Type 2 Diabetes

Official Title
-----------------
A Randomized, Double-Blind, Dose Ranging, Dose Comparison-Controlled Trial to Determine the Safety and Efficacy of BMS-298585 in Subjects With Type 2 Diabetes

Conditions
-----------------
Diabetes Mellitus II

Intervention / Treatment
-----------------
* Drug: Muraglitazar


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. HbA1c > 7.0% and ≤ 10.0% obtained at the Screening visit. 2. Men and women, 18-70 years of age Established Type 2 diabetes Exclusion Criteria: 1. Symptomatic Type 2 diabetes defined as marked polyuria and polydipsia with greater than 10% weight loss during the last three months. 2. Administration of antihyperglycemic agents (other than thiazolidinediones) for more than three consecutive or a total of seven non-consecutive days during the four weeks prior to screening. 3. Administration of thiazolidinediones for more than three consecutive or a total of seven non-consecutive days during the six weeks prior to screening.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Muraglitazar|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To compare, after 24 weeks of oral administration of double-blind treatment, the change from baseline in hemoglobin A1c (HbA1c) achieved with the highest dose and subsequent doses of BMS-298585 versus the lowest dose of BMS-298585 in subjects with Type 2 |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess, after 12 and 24 weeks of oral administration of double-blind therapy, the percent change from baseline in fasting lipids (total cholesterol,low density lipoprotein cholesterol,HDL-C, TG, non-HDL chol |  |  |